Anorexia nervosa remains one of the deadliest psychiatric disorders, disproportionately affecting young women and marked by severe physical deterioration and complex psychosocial symptoms. Among these symptoms, social impairments including diminished social networks and impaired emotional empathy are pronounced, yet poorly understood on a mechanistic level. Given psilocybin’s serotonergic activity and anti-inflammatory properties, the Monash team sought to dissect how this compound might influence behaviors entwined with serotonin system dysfunction and inflammatory processes, which are implicated across several psychiatric conditions including anorexia.

Prevailing research has largely centered on male subjects, a significant limitation considering the dominant female prevalence of anorexia. Addressing this gap, the researchers utilized female mice subjected to four distinct conditions: a combination of food restriction and voluntary wheel running to simulate ABA, food restriction alone, unlimited food with running wheel access, and standard housing controls. This experimental design enabled a rigorous examination of how metabolic stress, voluntary exercise, and their interactions modulate psilocybin’s behavioral and immunological effects.

Psilocybin was administered when mice in the ABA model reached a critical weight loss threshold, aligning with clinical conditions of anorexia nervosa. The subsequent social preference assays revealed unexpected behavioral profiles—contrary to anticipated social withdrawal, ABA mice demonstrated increased novelty-seeking, favoring novel social partners consistently. This hyperexploratory behavior toward unfamiliar mice was not replicated in food-restricted subjects without exercise, underscoring a fascinating interplay between metabolic challenge and physical activity.

Conversely, mice granted only wheel access without food limitation showed delayed novelty preference emerging during choice tests rather than initial exploration, suggesting that exercise alone primes different social cognitive circuits. Intriguingly, psilocybin administration did not universally enhance sociability but instead inverted typical novelty preferences in control animals, equalizing interactions between familiar and novel partners. In food-restricted, psilocybin-treated mice, a strong correlation emerged between lower body weight and increased motivation toward novel objects rather than social novelty, implying a context-dependent shift potentially linked to heightened food-seeking drives.

Immunological outcomes added further complexity. Contrary to human clinical data indicating elevated inflammatory markers in anorexia, baseline interleukin-6 (IL-6) levels in mouse models did not differ significantly across groups. However, mice with wheel access receiving psilocybin showed a marked elevation in IL-6 compared to all other cohorts, a surprising finding given psychedelics’ traditionally reported anti-inflammatory effects. Even more compelling, this IL-6 increase correlated positively with social novelty preference, hinting at an intricate modulatory axis involving metabolic reward, immune activation, and behavioral output.

These immune-behavior relationships were absent in the ABA and food restriction groups, suggesting that prior metabolic stress blunts or modifies the immune-sensory pathways engaged by psilocybin in exercising animals. The researchers speculate that exercise-induced dopamine pathway activation may create a unique immunometabolic milieu, enabling psilocybin’s divergent effects. The acute timing of sample collection—only hours post-administration—may also capture transient inflammatory responses preceding the longer-term anti-inflammatory benefits documented in human trials.

This meticulous dissection of metabolic, behavioral, and immune parameters challenges simplistic notions of psychedelics as universally beneficial and highlights the necessity of considering individual physiological contexts in therapeutic applications. The absence of expected social deficits in ABA mice, a surprising deviation from clinical symptomatology, points to the limitations of acute or short-term animal models and raises questions about the influence of chronicity, environmental factors, and psychosocial variables unmodeled in rodents.

Clinically, these findings carry profound implications. Psilocybin’s variable effects contingent on exercise and metabolic state hint at biomarkers—such as physical activity patterns or inflammatory status—that could refine patient selection and personalize treatment strategies for anorexia nervosa and related disorders. Additionally, dynamic monitoring of immune markers post-treatment could offer mechanistic insights and prognostic signals for responsiveness, addressing variability observed in current clinical trials where only a subset of participants achieve symptom remission.

Looking forward, the study charts clear avenues for future investigation, advocating for longer duration exposure paradigms mimicking cyclical fasting and refeeding characteristic of chronic anorexia. Temporal profiling of cytokine trajectories and employing a panel of inflammatory and neuroplasticity markers across brain regions will be critical for unraveling the complex temporal and spatial dimensions of psychedelic action. Importantly, a dual-sex investigative strategy is warranted given sex-specific neuropharmacological and behavioral dynamics, a gap this study begins to fill through its exclusive focus on females.

The Monash team’s work exemplifies the power of controlled comparative experimental frameworks in psychedelic research, challenging canonical assumptions and underscoring the profound interplay between neurochemical, immune, and behavioral systems modulated by metabolic context. Their integrative approach, coupling detailed phenotypic assessments with immune profiling, sets a new standard for preclinical investigations and paves the way for translational breakthroughs in the treatment of eating disorders.

Sheida Shadani, who conducted the experiments as part of her doctoral research, alongside Erika Greaves and under the guidance of Professors Zane B. Andrews and Associate Professor Claire Foldi, have contributed an impactful study funded by a National Health and Medical Research Council Ideas Grant. Their findings usher in a new paradigm of personalized psychedelic medicine, emphasizing that understanding the patient’s physiological state—beyond mere diagnosis—may hold the key to unlocking therapeutic efficacy.

This transformative research, freely accessible through the journal Psychedelics as of February 3, 2026, not only advances fundamental science but also invigorates the quest for innovative treatments tailored to the complex neurobiological and immunological realities of disorders like anorexia nervosa. By marrying rigorous methodology with clinical relevance, the study heralds a future where psychedelic therapies are harnessed with precision, maximizing benefit while navigating the subtleties of human physiology.

Subject of Research: Animals

Article Title: Psilocybin exerts differential effects on social behavior and inflammation in mice in contexts of activity-based anorexia

News Publication Date: 3-Feb-2026

Web References: https://doi.org/10.61373/pp026a.0003

Image Credits: Claire J Foldi

Keywords: Psilocybin, Activity-Based Anorexia, Female Mice, Social Behavior, Inflammation, Interleukin-6, Metabolic Stress, Exercise, Novelty-Seeking, Psychedelic Therapy, Eating Disorders, Preclinical Model

The study delves into the comparative analysis of gene expression profiles collected from a range of genetically engineered mice, each designed to recapitulate different aspects of schizophrenia pathology. What distinguishes this meta-analysis is its integrative approach, pooling datasets from distinct studies which individually explored variants of schizophrenia-related genes like DISC1, NRG1, or 22q11.2 deletions. By harmonizing these datasets, the authors surmounted limitations of single-model investigations, offering a panoramic view of transcriptomic perturbations that transcend individual genetic contexts. This approach is especially critical, given schizophrenia’s polygenic nature, where numerous genes of small effect collectively influence disease susceptibility and progression.

A core element of the findings centers on the striatum, a subcortical structure orchestrating motor control, reward processing, and cognitive functions. Disruptions within striatal circuits have been implicated in the psychomotor and motivational deficits commonly observed in schizophrenia patients. The meta-analysis uncovers consistent alterations in gene networks regulating synaptic transmission, neurotransmitter signaling, and neuronal metabolism within the striatum. These dysregulated gene clusters point toward a convergent pathogenic mechanism that impairs striatal communication, potentially leading to the aberrant dopaminergic activity frequently reported in schizophrenia. Such molecular insights refine prior hypotheses and pave the way for region-specific therapeutic targeting.

Equally compelling is the identification of marked transcriptome changes in the thalamus, a vital relay station funneling sensory and motor information to the cerebral cortex. The thalamus has garnered increasing attention in schizophrenia research due to observed structural and functional abnormalities correlated with cognitive and sensory gating deficits. This meta-analysis reveals that genes pivotal to thalamic connectivity, neurodevelopment, and synaptic plasticity are notably downregulated across models. This unified pattern of disrupted thalamic gene expression underscores the role of impaired thalamocortical communication in the emergence of schizophrenia’s hallmark symptoms, including hallucinations and cognitive fragmentation.

The methodology employed showcases the power of high-throughput RNA sequencing technologies coupled with sophisticated bioinformatic integration. By meticulously reanalyzing raw transcriptomic data through a uniform computational pipeline, the team minimized batch effects and technical variances inherent in cross-study comparisons. Advanced statistical frameworks, such as weighted gene co-expression network analysis (WGCNA), were utilized to map gene-gene interaction modules and identify hub genes central to the observed dysregulations. This systems biology approach transcends single-gene analyses, highlighting complex molecular circuits that might serve as biomarkers or therapeutic entry points.

Beyond identifying affected genes and pathways, the meta-analysis also delineates functional annotation of the transcriptomic alterations. Enrichment analyses revealed that pathways involved in synaptic vesicle cycling, glutamatergic and GABAergic neurotransmission, as well as mitochondrial function, were significantly disrupted in both striatal and thalamic samples. These convergent pathway disruptions vividly illustrate how schizophrenia might be rooted in the compromise of fundamental neural processes governing excitability, energy metabolism, and plasticity. The study’s insights tangibly integrate molecular data with clinical phenomenology, enhancing translational relevance.

Importantly, the cross-model consistency observed in this meta-analysis validates the utility of genetic mouse models as experimental proxies for human schizophrenia. By revealing overlapping molecular signatures despite varying genetic causes, the research supports the concept of a final common pathway of dysregulated brain circuits. This conceptual framework is crucial for directing future preclinical studies, enabling prioritization of candidate genes and networks for pharmacological modulation. Moreover, this validation encourages refinement of animal models to better replicate human disease phenotypes at the molecular and systems levels.

The implications of these findings extend well beyond basic science. From a therapeutic standpoint, targeting striatal and thalamic dysfunctions at the molecular level could revolutionize approaches to schizophrenia treatment. Current antipsychotics primarily manage positive symptoms through dopamine receptor antagonism but do little to address cognitive and negative symptoms. The newly identified transcriptomic networks offer fresh molecular targets that could enable the development of more effective, mechanism-based interventions. For instance, modulators of synaptic plasticity or mitochondrial resilience within these regions might ameliorate core deficits with improved efficacy and reduced side effects.

Furthermore, the methodological blueprint of this meta-analysis sets a precedent for tackling other complex neuropsychiatric disorders characterized by genetic heterogeneity and multifaceted neurobiology, such as bipolar disorder or autism spectrum disorder. Integrating multi-model transcriptomic data might similarly uncover shared dysregulated circuits and identify novel intervention points. This study thus exemplifies the evolving landscape of psychiatric genetics, where data-driven integrative analyses surmount traditional experimental limitations to generate deeper, system-wide understanding.

One cannot overlook the potential of these findings to inform biomarker discovery efforts. The consistent transcriptional signatures in the striatum and thalamus may manifest in peripheral tissues or cerebrospinal fluid, representing accessible proxies for disease monitoring and personalized medicine strategies. By capturing molecular fingerprints of schizophrenia with greater fidelity, blood-based or imaging biomarkers targeting gene expression networks might eventually enable earlier diagnosis and stratified patient care tailored to individual molecular profiles.

Nevertheless, the study also acknowledges inherent caveats of animal model research, including species-specific differences and incomplete recapitulation of human symptomatology. While the meta-analysis minimized protocol discrepancies and emphasized datadriven harmonization, translational gaps remain. Complementary research integrating human postmortem brain studies, single-cell sequencing, and in vivo functional analyses will be required to corroborate these findings and map the dynamic temporal evolution of transcriptomic dysregulation throughout illness course.

In conclusion, this seminal meta-analysis significantly advances our molecular understanding of schizophrenia by integrating brain transcriptomes across diverse genetic mouse models to identify robust dysregulation within the striatum and thalamus. This work underscores the convergent impact of schizophrenia-associated genes on critical subcortical circuits governing cognition, motivation, and sensory integration. By illuminating these shared molecular pathways, the study opens up fertile ground for designing innovative therapeutic approaches, improving biomarker discovery, and refining preclinical models. The emerging picture offers renewed hope for addressing the unmet clinical needs in schizophrenia and exemplifies the power of collaborative, integrative data analysis in psychiatric neuroscience.

The future of schizophrenia research lies in leveraging such sophisticated meta-analytic frameworks to constantly refine our grasp of its complex genetic architecture and neurobiology. Synergistic integration of transcriptomics, proteomics, and epigenetics, combined with longitudinal patient data, will further unravel disease heterogeneity and pathogenic mechanisms. Harnessing big data and computational biology not only helps decode schizophrenia’s enigma but also sets a transformative paradigm for other brain disorders. As we move forward, the bridge between preclinical models and clinical reality tightens, bringing us closer to tailored therapies and improved patient outcomes in this devastating illness.

Subject of Research: Genetic mouse models and transcriptomic analysis of schizophrenia focusing on brain regions striatum and thalamus

Article Title: Meta-analysis of the brain transcriptomes of multiple genetic mouse models of schizophrenia highlights dysregulation in striatum and thalamus

Article References:
Perzel Mandell, K.A., Simmons, S.K., Nadig, A. et al. Meta-analysis of the brain transcriptomes of multiple genetic mouse models of schizophrenia highlights dysregulation in striatum and thalamus. Transl Psychiatry 15, 345 (2025). https://doi.org/10.1038/s41398-025-03563-5

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41398-025-03563-5